Opioid receptors have emerged as pivotal targets in the quest to effectively manage pain, yet the medications that act on these receptors often carry a significant risk of addiction. More alarmingly, these drugs can lead to severe respiratory depression and cardiovascular complications, which can be fatal. However, researchers from the University of South Florida have recently made promising strides towards a long-held objective in pharmacology: developing a compound that can alleviate pain without the troubling side effects commonly associated with opioid use (Nature 2025, DOI: 10.1038/s41586-025-09880-5).
Opioid receptors fall under the category of G protein-coupled receptors (GPCRs), a class of membrane proteins crucial for cellular signaling. These receptors work by facilitating a complex interplay of proteins that transmit signals inside the cell, a process initiated when a ligand binds to the GPCR.
When an agonist like morphine or fentanyl attaches to an opioid receptor, it activates a G protein that binds to guanosine triphosphate (GTP) and sets off a cascade of biochemical reactions throughout the cell. Over time, this G protein converts GTP into a different molecule, which leads to its own inactivation.
Matthew Swanson, a graduate student involved in this recent study, likens the consumption of GTP to a car using fuel. He notes, "When you run out of gas, your car dies," highlighting the limitations of the traditional model.
For nearly ten years, Swanson's advisors, Professors Laura M. Bohn and Edward Stahl at USF, have presented a compelling case suggesting that GPCRs are capable of operating in a different manner. They propose that in certain active states, a GPCR can reclaim a GTP-bound effector, potentially enabling a more sustainable activation process. In his analogy, Swanson suggests, "Instead of us using that gasoline, we would just be running a battery," pointing to a more efficient way of signaling.
While the technical details may initially seem daunting, the implications are significant. By designing compounds that preferentially stabilize different active states of GPCRs, scientists could influence specific signaling pathways, allowing them to stimulate desired effects while avoiding unwanted ones. In the context of opioid receptors, the ultimate goal is to achieve pain relief without dampening essential functions such as respiration and heart rate.
Bohn, Stahl, Swanson, and their research team believe they have discovered a compound, muzepan1, that can effectively differentiate between these essential functions due to its unique interaction with the mu-opioid receptor. Muzepan1 appears to promote a GPCR state that resembles running on battery power rather than depleting fuel, which sets it apart from traditional agonists.
In experimental models, muzepan1 has demonstrated efficacy as an analgesic, reducing sensitivity to painful stimuli, including heat. What’s even more noteworthy is that when combined with conventional opioids like fentanyl, muzepan1 significantly enhances pain tolerance without exacerbating respiratory depression or lowering heart rate.
Despite these encouraging findings, it’s important to note that muzepan1 is not currently suitable for therapeutic use, and substantial questions remain regarding its synergistic interactions with other receptor agonists. Joann Trejo, a GPCR pharmacologist at the University of California, San Diego, emphasizes that further investigation is needed to fully grasp how this unique synergy operates, although she acknowledges that the evidence suggesting a distinctive interaction between muzepan1 and fentanyl is compelling. She describes the research team's exploration of a novel GPCR signaling mechanism as "outstanding."
Bohn and Stahl express their enthusiasm about discovering a new signaling mechanism that could delineate the beneficial effects of opioids on pain relief from their adverse impacts on critical physiological functions. This breakthrough may pave the way for safer pain management options in the future.
